The ether.fi app now uses Enso's infrastructure to enable routing, bridging, and execution across multiple blockchain protocols, supporting over 100 tokenized assets linked to stocks, metals, and cryptocurrencies. This integration simplifies cross-chain trading by comparing multiple quotes and abstracting complex processes, although swaps can take up to 15 minutes depending on the asset and trade size. The app also offers borrowing features via Aave on Optimism, allowing users to borrow against their portfolios at around 4% interest. However, tokenized stocks and metals are not available to users in the U.S. and certain other regions, highlighting regulatory limitations.
The Enso Powers Ether.fi app integration with over 100 tokenized assets provides context for readers. For those following the broader cryptocurrency market, here is Pluang's snapshot as of Sep 25, 2026 01:32 WIB: out of 50 major cryptocurrencies, 43 rose and 6 fell today. LINK gained 7.95% to Rp235.571 with a typical hold time of 63 days and 60% sell orders, FIL rose 7.63% to Rp17.897 with a 99-day hold and 62% sell activity, while XNO dropped 7.35% to Rp6.655 despite a 76% buy order share and an 85-day hold time.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
